亞太藥業(002370.SZ):控股股東所持2500萬股司法拍賣股份流拍
格隆匯 10 月 12日丨亞太藥業(002370.SZ)公佈,公司控股股東浙江亞太集團有限公司(“亞太集團”)及其子公司紹興柯橋亞太房地產有限公司(“亞太房地產”)因與浙商銀行股份有限公司紹興越城支行公證債權文書一案,浙江省紹興市中級人民法院於2020年10月11日10時至2020年10月12日10時止(延時的除外)在浙江省紹興市中級人民法院淘寶網司法拍賣網絡平台上(網址:http://sf.taobao.com,户名:浙江省紹興市中級人民法院)對亞太集團持有的公司2500萬股股份進行公開拍賣。根據淘寶網司法拍賣網絡平台頁面顯示的拍賣結果,此次拍賣流拍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.